Lilly Doubles Down on Insomnia with Hypnion Acquisition

Eli Lilly added its second insomnia program with the acquisition of privately held Hypnion Inc. Hypnion's Phase II HY10275 compound is the industry's most advanced dual H1/5HT2a antagonist in clinical development. Hypnion management told START-UP that M&A was its preferred exit, given the resources necessary to develop HY10275 to its full potential.

More from Strategy

More from Business